Verition Fund Management
TVRD

Verition Fund Management’s Tvardi Therapeutics TVRD Stock Holding History

Verition Fund Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,389
Closed -$12.9K – 3564
2024
Q2 		$12.9K Hold
1,389
– – ﹤0.01% 2884
2024
Q1 		$45.5K Buy
+1,389
New +$36K ﹤0.01% 2642

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Verition Fund Management's TVRD Position: Q2 2024 in Review

Verition Fund Management sold out of Tvardi Therapeutics (TVRD) in Q2 2024, closing a stake of 10,850 shares — an estimated $259K sold.

Verition Fund Management first reported a position in TVRD in Q2 2015 and held it in 6 quarters. The position peaked at $1.27M in Q2 2023. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.

  • Verition Fund Management reported no remaining Tvardi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Verition Fund Management sold 10,850 Tvardi Therapeutics shares in Q2 2024, an estimated $259K.
  • Verition Fund Management first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 6 quarters.
  • Verition Fund Management's Tvardi Therapeutics position peaked at $1.27M in Q2 2023.
  • 79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.

Based on Verition Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.